Companies / Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc.

Nasdaq: VTGNCIK 1411685SOUTH SAN FRANCISCO, CA

Financials · FY2023

Revenue$-227.0K
Net income$-69.69M
Total debt$105.0K
Cash$30.79M
Diluted EPS$-1.83
Shares outstanding41.0M

Ownership

41.0M shares outstanding · as of Jun 12, 2026
0.04%Insiders
Ownership
Insiders0.04%15,249
10%+ / strategic9.46%3,880,572
Institutions31.01%12,725,044
Public float59.49%24,411,588

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 1

View all →
Insider% of sharesShares
Prince Joshua S.Chief Operating Officer
0.04%15,249

Institutional holders 60

View all →
HolderValue% of shares
TCG Crossover Management, LLC$1.77M6.52%
Orbimed Advisors LLC$1.75M7.46%
Vanguard Group Inc$1.21M4.45%
ADAR1 Capital Management, LLC$412.7K1.52%
Jane Street Group, LLC$348.9K1.28%
Ikarian Capital, LLC$343.6K1.27%
Two Sigma Investments, LP$268.4K1.14%
Geode Capital Management, LLC$259.2K1.10%
Millennium Management LLC$246.0K1.05%
Luminus Management, LLC$226.3K0.97%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Dec 31, 2025Prince Joshua S.
Executive
GrantCommon Stock$2.5K+4K
+40.38%
15,249
0.04% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A—1,824,738—
Orbimed Advisors LLCPassive13G/A———
Janus Henderson Group PLCPassive13G/A———
Great Point Partners, LLCPassive13G/A—2,055,834—
Nantahala Capital Management, LLCPassive13G/A———
Stempoint Capital LPPassive13G/A———
Commodore Capital LPPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
VTGNCommon StockEquity92840H400BBG000BB33L9